Screening adults for MGUS and studying genetic and immune factors
Screens adults aged 40 and older for an abnormal blood protein called MGUS.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study
- Status
- Enrolling by invitation
- People taking part
- 1,000 people, planned
- Started
- 22 May 2024
- Expected to end
- 31 May 2029
- Type of study
- Observational
- Treatments tested
- Non-Interventional Study
- Record updated
- 11 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older to be screened for MGUS, a condition where an abnormal immune protein is found in the blood. It also studies genetic and immune factors linked to MGUS.
- Age
- 40 years or older
- Sex
- All sexes can join.
Main reasons for not taking part
- Pregnant women
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Adults ≥ 40 years
- Willing and able to review, understand, and provide consent before starting any study-specific procedures
- Ability to complete questionnaire(s) by themselves or with assistance
Who cannot take part
- Pregnant women
Where in United States
- Mayo Clinic in RochesterRochester, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.
The group in the trial
- Observational
Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.
Treatment: Non-Interventional Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study
- Plain-language title
- Screening adults for MGUS and studying genetic and immune factorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 August 2026